Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (20579)
All Articles published online
|
Publishing Process of This Article
|
Feb 24, 2020 (publication date) through Nov 26, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Clinical Oncology
ISSN
2218-4333
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Aykan NF, Özatlı T. Objective response rate assessment in oncology: Current situation and future expectations. World J Clin Oncol 2020; 11(2): 53-73 [PMID: 32133275 DOI: 10.5306/wjco.v11.i2.53] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v11/i2/53.htm |
| Number | Citing Articles |
| 1 |
Kostas Marias. The Constantly Evolving Role of Medical Image Processing in Oncology: From Traditional Medical Image Processing to Imaging Biomarkers and Radiomics. Journal of Imaging 2021; 7(8): 124 doi: 10.3390/jimaging7080124
|
| 2 |
Yasemin Söyler, Özlem Özmen, Pınar Akın Kabalak, Hakan Ertürk, Feza Uğurman, Ülkü Yılmaz. The efficacy of 18F-FDG PET/CT in monitoring disease progression in malignant pleural mesothelioma. Revista Española de Medicina Nuclear e Imagen Molecular (English Edition) 2023; 42(1): 3 doi: 10.1016/j.remnie.2022.09.005
|
| 3 |
Litao Huang, Deying Kang, Chongyang Zhao, Xueting Liu. Correlation between surrogate endpoints and overall survival in unresectable hepatocellular carcinoma patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis. Scientific Reports 2024; 14(1) doi: 10.1038/s41598-024-54945-6
|
| 4 |
Thomas Kelleher, Junliang Cai, Nicholas AJ Botwood, Dominic F Labriola. Characterizing tumor shrinkage as a measure of clinical benefit for immune checkpoint inhibitors. Journal for ImmunoTherapy of Cancer 2021; 9(2): e001177 doi: 10.1136/jitc-2020-001177
|
| 5 |
T. M. Zimina, K. G. Gareev, N. O. Sitkov, K. E. Brusina, M. A. Shubina, Zh. Ganiev, D. E. Bobkov, R. B. Likhomanova, N. M. Yudintseva, N. N. Potrakhov, M. A. Shevtsov. A device for studying heterogeneous tumor cell cultures based on a hybrid microfluidic system. Biomedical Engineering 2024; 58(3): 153 doi: 10.1007/s10527-024-10386-z
|
| 6 |
Inga Trulson, Stefan Holdenrieder, Stefan Holdenrieder, Huub van Rossum, Michel van den Heuvel. Prognostic value of blood-based protein biomarkers in non-small cell lung cancer: A critical review and 2008–2022 update. Tumor Biology 2024; 46(s1): S111 doi: 10.3233/TUB-230009
|
| 7 |
Jia Tan, Chang Liu, Yan Li, Yiqi Ma, Ruoxi Xie, Zheng Li, Hengjiang Wan, Su Lui, Min Wu. Assessment of immunotherapy response in intracranial malignancy using semi-automatic segmentation on magnetic resonance images. Frontiers in Immunology 2022; 13 doi: 10.3389/fimmu.2022.1029656
|
| 8 |
Azadeh Tabari, Brian D’Amore, Janice Noh, Michael S. Gee, Dania Daye. Quantitative peritumoral magnetic resonance imaging fingerprinting improves machine learning-based prediction of overall survival in colorectal cancer. Exploration of Targeted Anti-tumor Therapy 2024; 5(1): 74 doi: 10.37349/etat.2024.00205
|
| 9 |
Kwanjoo Lee, Jae Seung Lee, Do Young Kim. Transarterial chemoembolization versus radioembolization as a
treatment option for single large (>5 cm) hepatocellular carcinoma: a
retrospective study in South Korea. Life Cycle 2023; 3 doi: 10.54724/lc.2023.e13
|
| 10 |
Paritosh N Bhangale, Shivali V Kashikar, Paschyanti R Kasat, Priyal Shrivastava, Anjali Kumari. A Comprehensive Review on the Role of MRI in the Assessment of Supratentorial Neoplasms: Comparative Insights Into Adult and Pediatric Cases. Cureus 2024; doi: 10.7759/cureus.67553
|
| 11 |
Ketki S Dantkale, Manjusha Agrawal. A Comprehensive Review of Current Trends in the Diagnosis and Treatment of Ovarian Germ Cell Tumors. Cureus 2024; doi: 10.7759/cureus.52650
|
| 12 |
Ewan Hunter, Matthew Salter, Ryan Powell, Ann Dring, Tarun Naithani, Maria Eleni Chatziioannou, Abel Gebregzabhar, Mutaz Issa, Jayne Green, Serene Ng, Chun Ren Lim, Cheah Soon Keat, Ang Tick Suan, Rakesh Raman, Ho Kean Fatt, Fabian Lee Wei Luen, Heba Alshaker, Dmitri Pchejetski, Dave Blum, Thomas Guiel, Robert Heaton, Jedd Levine, Alexandre Akoulitchev. Development and Validation of Blood-Based Predictive Biomarkers for Response to PD-1/PD-L1 Checkpoint Inhibitors: Evidence of a Universal Systemic Core of 3D Immunogenetic Profiling across Multiple Oncological Indications. Cancers 2023; 15(10): 2696 doi: 10.3390/cancers15102696
|
| 13 |
Daniel-Clement Osei-Bordom, Sivesh Kamarajah, Niki Christou. Colorectal Cancer, Liver Metastases and Biotherapies. Biomedicines 2021; 9(8): 894 doi: 10.3390/biomedicines9080894
|
| 14 |
Abhishek Mahajan, Nivedita Chakrabarty, Jinita Majithia, Ankita Ahuja, Ujjwal Agarwal, Shubham Suryavanshi, Mahesh Biradar, Prerit Sharma, Bagyam Raghavan, Rasheed Arafath, Shreya Shukla. Multisystem Imaging Recommendations/Guidelines: In the Pursuit of Precision Oncology. Indian Journal of Medical and Paediatric Oncology 2023; 44(01): 002 doi: 10.1055/s-0043-1761266
|
| 15 |
Fanli Zhou, Zhidong Yuan, Xianglin Liu, Keyan Yu, Bowei Li, Xingyan Li, Xin Liu, Guanxun Cheng. Evaluation of atrial anatomical remodeling in atrial fibrillation with machine-learned morphological features. International Journal of Computer Assisted Radiology and Surgery 2022; 18(4): 603 doi: 10.1007/s11548-022-02776-z
|
| 16 |
Maria Rosaria Ruggiero, Simona Baroni, Valeria Bitonto, Roberto Ruiu, Smeralda Rapisarda, Silvio Aime, Simonetta Geninatti Crich. Intracellular Water Lifetime as a Tumor Biomarker to Monitor Doxorubicin Treatment via FFC-Relaxometry in a Breast Cancer Model. Frontiers in Oncology 2021; 11 doi: 10.3389/fonc.2021.778823
|
| 17 |
Nicholas J. Schork, Laura H. Goetz, James Lowey, Jeffrey Trent. Strategies for Testing Intervention Matching Schemes in Cancer. Clinical Pharmacology & Therapeutics 2020; 108(3): 542 doi: 10.1002/cpt.1947
|
| 18 |
Yong-Jin Park, Seung Hyup Hyun, Seung Hwan Moon, Kyung-Han Lee, Byung Hoon Min, Jun Haeng Lee, Won Seog Kim, Seok Jin Kim, Joon Young Choi. Role in staging and prognostic value of pretherapeutic F-18 FDG PET/CT in patients with gastric MALT lymphoma without high-grade transformation. Scientific Reports 2021; 11(1) doi: 10.1038/s41598-021-88815-2
|
| 19 |
Fangzhou He, Lu Xie, Xin Sun, Jie Xu, Yuan Li, Rong Liu, Kunkun Sun, Danhua Shen, Jin Gu, Tao Ji, Wei Guo. A Scoring System for Predicting Neoadjuvant Chemotherapy Response in Primary High‐Grade Bone Sarcomas: A Multicenter Study. Orthopaedic Surgery 2022; 14(10): 2499 doi: 10.1111/os.13469
|
| 20 |
Mark Jesus M. Magbanua, Wen Li, Laura J. van ’t Veer. Integrating Imaging and Circulating Tumor DNA Features for Predicting Patient Outcomes. Cancers 2024; 16(10): 1879 doi: 10.3390/cancers16101879
|
| 21 |
Daniel Zeitouni, Michael P. Catalino, Jordan Wise, Sean McCabe, Kathryn Pietrosimone, Naim Rashid, Simon Khagi. Clinical Application of Next-Generation Sequencing in Recurrent Glioblastoma. Onco 2021; 1(1): 38 doi: 10.3390/onco1010005
|
| 22 |
Amani A. Alrehaili, Amal F. Gharib, Maha M. Bakhuraysah, Afaf Alharthi, Ohud Alsalmi, Fouzeyyah Ali Alsaeedi, Reem Ali Alhakami, Kamilah Ali Alasmari, Nuha Mohammed, Wael H. Elsawy. Serum Pro-Inflammatory Cytokines and Leptin as Potential Biomarkers for Treatment Response and Toxicity in Locally Advanced Squamous Cell Carcinoma of the Head and Neck. Diseases 2024; 12(3): 55 doi: 10.3390/diseases12030055
|
| 23 |
Yuze Li, Ziming Xu, Chao An, Huijun Chen, Xiao Li. Multi-Task Deep Learning Approach for Simultaneous Objective Response Prediction and Tumor Segmentation in HCC Patients with Transarterial Chemoembolization. Journal of Personalized Medicine 2022; 12(2): 248 doi: 10.3390/jpm12020248
|
| 24 |
Ahmed Nassar, Amir Abdelhamid, George Ramsay, Mohamed Bekheit. Chronomodulated Administration of Chemotherapy in Advanced Colorectal Cancer: A Systematic Review and Meta-Analysis. Cureus 2023; doi: 10.7759/cureus.36522
|
| 25 |
Adnan Ahmad, Mohammad Haneef, Shadma Khan, Fariya Khan, Nabeel Ahmad, Saif Khan, Samriddhi Jaswani. CAR T‑cell immunotherapy: A safe and potent living drug technique for cancer treatment (Review). World Academy of Sciences Journal 2023; 5(4) doi: 10.3892/wasj.2023.200
|
| 26 |
Ines Horvat-Menih, Hao Li, Andrew N. Priest, Shaohang Li, Andrew B. Gill, Iosif A. Mendichovszky, Susan T. Francis, Anne Y. Warren, Brent O’Carrigan, Sarah J. Welsh, James O. Jones, Antony C. P. Riddick, James N. Armitage, Thomas J. Mitchell, Grant D. Stewart, Ferdia A. Gallagher. High-resolution and highly accelerated MRI T2 mapping as a tool to characterise renal tumour subtypes and grades. European Radiology Experimental 2024; 8(1) doi: 10.1186/s41747-024-00476-8
|
| 27 |
Konstantinos Vrontis, Sofia C. Economidou, George Fotopoulos. Platinum Doublet plus Atezolizumab as First-line Treatment in Metastatic Large Cell Neuroendocrine Carcinoma: A Single Institution Experience. Cancer Investigation 2022; 40(2): 124 doi: 10.1080/07357907.2021.1988962
|
| 28 |
Haitang CHEN, Renliang LI, Jiaohong WU. The efficacy of tyrosine kinase inhibitors combined with chemotherapy for recurrent ovarian cancer: a systematic review and network meta-analysis. Minerva Biotechnology and Biomolecular Research 2024; 36(2) doi: 10.23736/S2724-542X.24.03085-2
|
| 29 |
Samantha M. Ruff, Zachary J. Brown, Timothy M. Pawlik. A review of targeted therapy and immune checkpoint inhibitors for metastatic colorectal cancer. Surgical Oncology 2023; 51: 101993 doi: 10.1016/j.suronc.2023.101993
|
| 30 |
Zhaoshi Bao, Shouwei Li, Liang Wang, Bisi Zhang, Peilong Zhang, Hepeng Shi, Xiaoguang Qiu, Tao Jiang. PTPRZ1-METFUsion GENe (ZM-FUGEN) trial: study protocol for a multicentric, randomized, open-label phase II/III trial. Chinese Neurosurgical Journal 2023; 9(1) doi: 10.1186/s41016-023-00329-0
|
| 31 |
Y. Söyler, Ö. Özmen, P.A. Kabalak, H. Ertürk, F. Uğurman, Ü. Yılmaz. La eficacia de [18F]FDG PET/TC en el seguimiento de la progresión de la enfermedad en el mesotelioma pleural maligno. Revista Española de Medicina Nuclear e Imagen Molecular 2023; 42(1): 3 doi: 10.1016/j.remn.2022.06.005
|
| 32 |
Jiayu Wang, Dana Al-Majid, J. Chad Brenner, Joshua D. Smith. Mutant HRas Signaling and Rationale for Use of Farnesyltransferase Inhibitors in Head and Neck Squamous Cell Carcinoma. Targeted Oncology 2023; 18(5): 643 doi: 10.1007/s11523-023-00993-3
|
| 33 |
Cinzia Dello Russo, Pierluigi Navarra. Local Investigators Significantly Overestimate Overall Response Rates Compared to Blinded Independent Central Reviews in Uncontrolled Oncology Trials: A Comprehensive Review of the Literature. Frontiers in Pharmacology 2022; 13 doi: 10.3389/fphar.2022.858354
|
| 34 |
Laura Schomburg, Amer Malouhi, Marc-Oliver Grimm, Maja Ingwersen, Susan Foller, Katharina Leucht, Ulf Teichgräber. iRECIST-based versus non-standardized free text reporting of CT scans for monitoring metastatic renal cell carcinoma: a retrospective comparison. Journal of Cancer Research and Clinical Oncology 2022; 148(8): 2003 doi: 10.1007/s00432-022-03997-0
|
| 35 |
Takuto Nosaka, Yosuke Murata, Yu Akazawa, Kazuto Takahashi, Tatsushi Naito, Hidetaka Matsuda, Masahiro Ohtani, Yasunari Nakamoto. Changes of circulating tumor cells expressing CD90 and EpCAM in early-phase of atezolizumab and bevacizumab for hepatocellular carcinoma. Heliyon 2024; 10(14): e34441 doi: 10.1016/j.heliyon.2024.e34441
|
| 36 |
Natale Quartuccio, Vincenzo Militano, Marco Pappalardo, Luca Filippi, Oreste Bagni, Antonino Maria Moreci, Salvatore Ialuna. The Objective Response and Disease Control Rates in Patients with Liver Metastastic Breast Cancer Receiving Transarterial Radioembolization: A Meta-Analysis. Current Oncology 2024; 31(11): 6879 doi: 10.3390/curroncol31110508
|
| 37 |
Yan-Ping Fu, Hao Lin, Yu-Che Ou, Chen-Hsuan Wu, Hung-Chun Fu. Bevacizumab as a mitigating factor for the impact of high systemic immune-inflammation index on chemorefractory in advanced epithelial ovarian cancer. BMC Cancer 2024; 24(1) doi: 10.1186/s12885-024-13087-8
|
| 38 |
Nabeel Mansour, Kathrin Heinrich, Danmei Zhang, Michael Winkelmann, Maria Ingenerf, Lukas Gold, Konstantin Klambauer, Martina Rudelius, Frederick Klauschen, Michael von Bergwelt-Baildon, Jens Ricke, Volker Heinemann, C. Benedikt Westphalen, Wolfgang G. Kunz. Patient eligibility for trials with imaging response assessment at the time of molecular tumor board presentation. Cancer Imaging 2024; 24(1) doi: 10.1186/s40644-024-00708-5
|
| 39 |
Suji Udayakumar, Ambica Parmar, Natasha B. Leighl, Louis Everest, Vanessa S. Arciero, Seanthel Delos Santos, Amanda Rahmadian, Mark K. Doherty, Kelvin K.W. Chan. Pembrolizumab alone or with chemotherapy for metastatic non-small-cell lung cancer: A systematic review and network meta-analysis. Critical Reviews in Oncology/Hematology 2022; 173: 103660 doi: 10.1016/j.critrevonc.2022.103660
|
| 40 |
Faruque Azam, Alexei Vazquez. Trends in Phase II Trials for Cancer Therapies. Cancers 2021; 13(2): 178 doi: 10.3390/cancers13020178
|
| 41 |
Azadeh Tabari, Meredith Cox, Brian D’Amore, Arian Mansur, Harika Dabbara, Genevieve Boland, Michael S. Gee, Dania Daye. Machine Learning Improves the Prediction of Responses to Immune Checkpoint Inhibitors in Metastatic Melanoma. Cancers 2023; 15(10): 2700 doi: 10.3390/cancers15102700
|
| 42 |
Qian-Yu Yang, Lin Zhu, Hong-Xia Liu, Qing-Shan Zheng, Lu-Jin Li. Quantitative comparison of the efficacies and safety profiles of three first-line non-platinum chemotherapy regimens for advanced non-small cell lung cancer. Frontiers in Pharmacology 2022; 13 doi: 10.3389/fphar.2022.806728
|
| 43 |
Fang-Ying Chiu, Yun Yen. Imaging biomarkers for clinical applications in neuro-oncology: current status and future perspectives. Biomarker Research 2023; 11(1) doi: 10.1186/s40364-023-00476-7
|
| 44 |
Steffen Ventz, Leah Comment, Bill Louv, Rifaquat Rahman, Patrick Y Wen, Brian M Alexander, Lorenzo Trippa. The use of external control data for predictions and futility interim analyses in clinical trials. Neuro-Oncology 2022; 24(2): 247 doi: 10.1093/neuonc/noab141
|
| 45 |
Maria Isabella Donegani, Giulia Ferrarazzo, Stefano Marra, Alberto Miceli, Stefano Raffa, Matteo Bauckneht, Silvia Morbelli. Positron Emission Tomography-Based Response to Target and Immunotherapies in Oncology. Medicina 2020; 56(8): 373 doi: 10.3390/medicina56080373
|
| 46 |
Cinzia Dello Russo, Natalia Cappoli, Daniela Pilunni, Pierluigi Navarra. Local Investigators Significantly Overestimate Overall Response Rates Compared to Blinded Independent Central Reviews in Phase 2 Oncology Trials. The Journal of Clinical Pharmacology 2021; 61(6): 810 doi: 10.1002/jcph.1790
|
| 47 |
Bairu Zhang, Lukasz Magiera, Juliana Candido, Olga Muraeva, Jane Coates Ulrichsen, Jim Eyles, Elena Galvani, Natasha A. Karp. Bayesian modeling for analyzing heterogeneous response in preclinical mouse tumor models. Science Translational Medicine 2024; 16(771) doi: 10.1126/scitranslmed.adi9004
|
| 48 |
A Beginner's Guide to Targeted Cancer Treatments and Cancer Immunotherapy. 2025; : 253 doi: 10.1002/9781119834090.ch5
|
| 49 |
Nathan A. Pennell. Strategies and End Points in the Development of Novel Immunotherapy Trials for Patients With Unresectable, Locally Advanced Non–Small-Cell Lung Cancer. Journal of Clinical Oncology 2022; 40(29): 3353 doi: 10.1200/JCO.22.00827
|